ATR抑制剂AZD6738联合放疗提高NSCLC临床前模型治疗指数
该临床前研究评估ATR抑制剂AZD6738联合放疗对非小细胞肺癌(NSCLC)模型及放射性肺纤维化小鼠模型的影响。AZD6738特异性抑制ATR激酶,在NSCLC细胞中增强放射生物学反应,而在正常人支气管上皮细胞(HBEC)中无此效应。H460细胞源性移植瘤(CDX)中观察到显著肿瘤生长延迟(p<0.05),A549细胞中该效应较弱。联合放疗未显著改变CBCT肺组织密度(p>0.5)及放射性纤维化组织学评分(p>0.5)。结论认为ATR抑制联合放疗可增加肿瘤生长延迟而不增加晚期放射性毒性,支持向NSCLC临床评估转化。
要点
- AZD6738特异性抑制ATR激酶,在NSCLC细胞中增强放射反应,正常HBEC中无此效应。
- H460 CDX模型中联合治疗显著延迟肿瘤生长(p<0.05),A549中效应较弱。
- 联合放疗未显著增加放射性肺纤维化(CBCT密度p>0.5,组织学评分p>0.5)。
核心结论
- ATR抑制剂AZD6738联合放疗可增加NSCLC肿瘤生长延迟,且未观察到晚期放射性毒性增加,支持向临床评估转化。
研究设计与样本
- 临床前研究,在体外及体内使用A549和H460 NSCLC模型评估AZD6738单药及联合放疗,并用小鼠模型评估放射性肺纤维化。
主要发现
- AZD6738特异性抑制ATR激酶,在NSCLC模型中增强放射生物学反应,但在人支气管上皮细胞(HBEC)体外无此增强。
- H460细胞源性移植瘤(CDX)中观察到显著肿瘤生长延迟(p<0.05),A549细胞中该效应较不显著。
- 联合放疗后CBCT肺组织密度无显著变化(p>0.5),放射性纤维化组织学评分无显著变化(p>0.5)。
临床怎么用
- 该临床前结果提示ATR抑制联合放疗可能提高NSCLC治疗指数,支持后续临床评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To evaluate the impact of ATR inhibition using AZD6738 in combination with radiotherapy on the response of non-small cell lung cancer (NSCLC) tumour models and a murine model of radiation induced fibrosis. MATERIALS AND METHODS: AZD6738 was evaluated as a monotherapy and in combination with radiation in vitro and in vivo using A549 and H460 NSCLC models. Radiation induced pulmonary fibrosis was evaluated by cone beam computed tomography (CBCT) and histological staining. RESULTS: AZD6738 specifically inhibits ATR kinase and enhanced radiobiological response in NSCLC models but not in human bronchial epithelial cells (HBECs) in vitro. Significant tumour growth delay was observed in cell line derived xenografts (CDXs) of H460 cells (p<0.05) which were less significant in A549 cells. Combination of AZD6738 with radiotherapy showed no significant change in lung tissue density by CBCT (p>0.5) and histological scoring of radiation induced fibrosis (p>0.5). CONCLUSION: Inhibition of ATR with AZD6738 in combination with radiotherapy increases tumour growth delay without observable augmentation of late radiation induced toxicity further underpinning translation towards clinical evaluation in NSCLC.
引用
- Dunne V, Ghita M, Small DM, et al. Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of non-small cell lung cancer (NSCLC) radiotherapy. Radiother Oncol. 2017. PMID: 28697853. doi:10.1016/j.radonc.2017.06.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。